GB1219606A
(en)
|
1968-07-15 |
1971-01-20 |
Rech S Et D Applic Scient Soge |
Quinuclidinol derivatives and preparation thereof
|
US3657744A
(en)
|
1970-05-08 |
1972-04-25 |
Univ Minnesota |
Method for fixing prosthetic implants in a living body
|
US4733665C2
(en)
|
1985-11-07 |
2002-01-29 |
Expandable Grafts Partnership |
Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
|
US5350395A
(en)
|
1986-04-15 |
1994-09-27 |
Yock Paul G |
Angioplasty apparatus facilitating rapid exchanges
|
US5061273A
(en)
|
1989-06-01 |
1991-10-29 |
Yock Paul G |
Angioplasty apparatus facilitating rapid exchanges
|
US4748982A
(en)
|
1987-01-06 |
1988-06-07 |
Advanced Cardiovascular Systems, Inc. |
Reinforced balloon dilatation catheter with slitted exchange sleeve and method
|
CA1322628C
(en)
|
1988-10-04 |
1993-10-05 |
Richard A. Schatz |
Expandable intraluminal graft
|
GB8916480D0
(en)
|
1989-07-19 |
1989-09-06 |
Glaxo Group Ltd |
Chemical process
|
US6344053B1
(en)
|
1993-12-22 |
2002-02-05 |
Medtronic Ave, Inc. |
Endovascular support device and method
|
US5674278A
(en)
|
1989-08-24 |
1997-10-07 |
Arterial Vascular Engineering, Inc. |
Endovascular support device
|
US5292331A
(en)
|
1989-08-24 |
1994-03-08 |
Applied Vascular Engineering, Inc. |
Endovascular support device
|
GB8923590D0
(en)
|
1989-10-19 |
1989-12-06 |
Pfizer Ltd |
Antimuscarinic bronchodilators
|
CS277070B6
(en)
|
1989-12-22 |
1992-11-18 |
Adamovske Strojirny Np |
Device for the control of printing pressures
|
PT100441A
(pt)
|
1991-05-02 |
1993-09-30 |
Smithkline Beecham Corp |
Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
|
WO1993019750A1
(en)
|
1992-04-02 |
1993-10-14 |
Smithkline Beecham Corporation |
Compounds useful for treating allergic or inflammatory diseases
|
US5552438A
(en)
|
1992-04-02 |
1996-09-03 |
Smithkline Beecham Corporation |
Compounds useful for treating allergic and inflammatory diseases
|
US5605923A
(en)
|
1992-04-02 |
1997-02-25 |
Smithkline Beecham Corporation |
Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
|
GB9301000D0
(en)
|
1993-01-20 |
1993-03-10 |
Glaxo Group Ltd |
Chemical compounds
|
GB9414193D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
GB9414208D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
US5759787A
(en)
|
1996-08-26 |
1998-06-02 |
Tularik Inc. |
Kinase assay
|
GB9622386D0
(en)
|
1996-10-28 |
1997-01-08 |
Sandoz Ltd |
Organic compounds
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
US6166037A
(en)
|
1997-08-28 |
2000-12-26 |
Merck & Co., Inc. |
Pyrrolidine and piperidine modulators of chemokine receptor activity
|
WO1999016766A1
(fr)
|
1997-10-01 |
1999-04-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Derives de benzodioxole
|
GB9723566D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
GB9723590D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
GB9723589D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
YU44900A
(sh)
|
1998-01-31 |
2003-01-31 |
Glaxo Group Limited |
Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
|
CO4990969A1
(es)
|
1998-02-14 |
2000-12-26 |
Glaxo Group Ltd |
Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
|
GB9813535D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
GB9813565D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
KR20010071591A
(ko)
|
1998-06-23 |
2001-07-28 |
그레이엄 브레레톤, 레슬리 에드워즈 |
2-(퓨린-9-일)-테트라히드로푸란-3,4-디올 유도체
|
GB9813540D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
WO2000000531A1
(en)
|
1998-06-30 |
2000-01-06 |
The Dow Chemical Company |
Polymer polyols and a process for the production thereof
|
WO2000023457A1
(en)
|
1998-10-16 |
2000-04-27 |
Pfizer Limited |
Adenine derivatives
|
GB9913083D0
(en)
|
1999-06-04 |
1999-08-04 |
Novartis Ag |
Organic compounds
|
RU2266281C2
(ru)
|
1999-05-04 |
2005-12-20 |
Шеринг Корпорейшн |
Производные пиперидина, фармацевтическая композиция на их основе и способ лечения инфекции вирусом hiv
|
CZ20013940A3
(cs)
|
1999-05-04 |
2002-04-17 |
Schering Corporation |
Piperazinové deriváty uľitečné jako CCR5 antagonisté
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
US6322771B1
(en)
|
1999-06-18 |
2001-11-27 |
University Of Virginia Patent Foundation |
Induction of pharmacological stress with adenosine receptor agonists
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
SI1212089T1
(sl)
|
1999-08-21 |
2006-08-31 |
Altana Pharma Ag |
Sinergisticna kombinacija roflumilasta in salmeterola
|
CO5180581A1
(es)
|
1999-09-30 |
2002-07-30 |
Pfizer Prod Inc |
Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
|
EP1223952B1
(en)
|
1999-10-07 |
2008-04-16 |
Carlos Estuardo Aguilar-Cordova |
Methods for treatment of solid tumors and metastasis by gene therapy
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
GB0003960D0
(en)
|
2000-02-18 |
2000-04-12 |
Pfizer Ltd |
Purine derivatives
|
TWI227240B
(en)
|
2000-06-06 |
2005-02-01 |
Pfizer |
2-aminocarbonyl-9H-purine derivatives
|
GB0015727D0
(en)
|
2000-06-27 |
2000-08-16 |
Pfizer Ltd |
Purine derivatives
|
HU229306B1
(en)
|
2000-06-27 |
2013-10-28 |
L V A T Lab Sa |
Carbamates derived from arylalkylamines
|
GB0015876D0
(en)
|
2000-06-28 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
DE10038639A1
(de)
|
2000-07-28 |
2002-02-21 |
Schering Ag |
Nichtsteroidale Entzündungshemmer
|
CA2417825C
(en)
|
2000-08-05 |
2008-07-22 |
Glaxo Group Limited |
6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
US20030165902A1
(en)
*
|
2000-09-29 |
2003-09-04 |
Bieglecki Karyn M. |
Haplotypes of the F2R gene
|
US6423546B1
(en)
*
|
2000-11-02 |
2002-07-23 |
Miller Brewing Company |
Monoclonal antibodies for assaying lipid transfer proteins
|
WO2002063046A1
(en)
*
|
2000-11-09 |
2002-08-15 |
Genaissance Pharmaceuticals, Inc. |
Haplotypes of the tacr2 gene
|
WO2002055534A2
(en)
*
|
2000-11-10 |
2002-07-18 |
Genaissance Pharmaceuticals |
Haplotypes of the f2rli gene
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
KR100869722B1
(ko)
|
2000-12-22 |
2008-11-21 |
알미랄 에이쥐 |
퀴누클리딘 카르바메이트 유도체 및 m3 길항제로서 그의사용
|
ATE334128T1
(de)
|
2000-12-28 |
2006-08-15 |
Almirall Prodesfarma Ag |
Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
|
EP1241176A1
(en)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Purine derivatives for the treatment of ischemia
|
US7291608B2
(en)
|
2001-04-30 |
2007-11-06 |
Glaxo Group Limited |
Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
|
MXPA03010787A
(es)
|
2001-05-25 |
2004-03-02 |
Pfizer |
Un agonista del receptor a2a de adenosina en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas.
|
US20040248867A1
(en)
|
2001-06-12 |
2004-12-09 |
Keith Biggadike |
Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
|
EP2327766B1
(en)
|
2001-06-21 |
2015-12-02 |
BASF Enzymes LLC |
Nitrilases
|
EP1438309A1
(en)
|
2001-10-17 |
2004-07-21 |
Ucb, S.A. |
Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
|
GB0125259D0
(en)
|
2001-10-20 |
2001-12-12 |
Glaxo Group Ltd |
Novel compounds
|
AR037517A1
(es)
|
2001-11-05 |
2004-11-17 |
Novartis Ag |
Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
|
WO2003048181A1
(en)
|
2001-12-01 |
2003-06-12 |
Glaxo Group Limited |
17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
|
EP1461336B1
(en)
|
2001-12-20 |
2013-05-22 |
CHIESI FARMACEUTICI S.p.A. |
1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
|
AU2003202044A1
(en)
|
2002-01-15 |
2003-09-09 |
Glaxo Group Limited |
17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
|
AU2003201693A1
(en)
|
2002-01-21 |
2003-09-02 |
Glaxo Group Limited |
Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
|
GB0202216D0
(en)
|
2002-01-31 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
CA2477764A1
(en)
|
2002-03-26 |
2003-10-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
MXPA04009329A
(es)
|
2002-03-26 |
2005-01-25 |
Boehringer Ingelheim Pharma |
Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y usos de los mismos.
|
US20090170803A1
(en)
|
2002-04-10 |
2009-07-02 |
Linden Joel M |
Adjunctive treatment of biological diseases
|
ES2206021B1
(es)
|
2002-04-16 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de pirrolidinio.
|
ES2201907B1
(es)
|
2002-05-29 |
2005-06-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
|
DE10224888A1
(de)
|
2002-06-05 |
2003-12-24 |
Merck Patent Gmbh |
Pyridazinderivate
|
US7074806B2
(en)
|
2002-06-06 |
2006-07-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
DE10225574A1
(de)
|
2002-06-10 |
2003-12-18 |
Merck Patent Gmbh |
Aryloxime
|
DE10227269A1
(de)
|
2002-06-19 |
2004-01-08 |
Merck Patent Gmbh |
Thiazolderivate
|
ES2282667T3
(es)
|
2002-06-25 |
2007-10-16 |
Merck Frosst Canada Ltd. |
Inhibidores de pde4 8-(biaril)quinolinas.
|
ES2204295B1
(es)
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
EP1519922A1
(en)
|
2002-07-02 |
2005-04-06 |
Merck Frosst Canada & Co. |
Di-aryl-substituted ethane pyridone pde4 inhibitors
|
ES2518940T3
(es)
|
2002-07-08 |
2014-11-06 |
Pfizer Products Inc. |
Moduladores del receptor de glucocorticoides
|
AR040962A1
(es)
|
2002-08-09 |
2005-04-27 |
Novartis Ag |
Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
|
US20060167001A1
(en)
|
2002-08-10 |
2006-07-27 |
Sterk Jan G |
Pyridazinone-derivatives as pde4 inhibitors
|
US20060166995A1
(en)
|
2002-08-10 |
2006-07-27 |
Altana Pharma Ag |
Piperidine-n-oxide-derivatives
|
AU2003258576B2
(en)
|
2002-08-10 |
2009-07-30 |
Takeda Gmbh |
Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors
|
SE0202483D0
(sv)
|
2002-08-21 |
2002-08-21 |
Astrazeneca Ab |
Chemical compounds
|
US7288562B2
(en)
|
2002-08-23 |
2007-10-30 |
Ranbaxy Laboratories Limited |
Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
|
DE60311662T2
(de)
|
2002-08-29 |
2007-10-25 |
Altana Pharma Ag |
3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
|
ATE348616T1
(de)
|
2002-08-29 |
2007-01-15 |
Altana Pharma Ag |
2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
|
RU2005111225A
(ru)
|
2002-09-18 |
2005-08-27 |
Оно Фармасьютикал Ко., Лтд. (Jp) |
Производные триазаспиро[5.5]ундекана и лекарственные средства, содержащие их в качестве активного ингредиента
|
JP2006096662A
(ja)
|
2002-09-18 |
2006-04-13 |
Sumitomo Pharmaceut Co Ltd |
新規6−置換ウラシル誘導体及びアレルギー性疾患の治療剤
|
JP2004107299A
(ja)
|
2002-09-20 |
2004-04-08 |
Japan Energy Corp |
新規1−置換ウラシル誘導体及びアレルギー性疾患の治療剤
|
DE10246374A1
(de)
|
2002-10-04 |
2004-04-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
JP2006506379A
(ja)
|
2002-10-23 |
2006-02-23 |
グレンマーク・ファーマシューティカルズ・リミテッド |
炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物:その調製方法およびそれらを含む医薬組成物
|
GB0225535D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0225540D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
DE10253282A1
(de)
|
2002-11-15 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
|
DE10253220A1
(de)
|
2002-11-15 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
DE10253426B4
(de)
|
2002-11-15 |
2005-09-22 |
Elbion Ag |
Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
MXPA06001989A
(es)
*
|
2003-08-18 |
2006-05-17 |
Pfizer Prod Inc |
Programa de dosificacion para un nuevo agente anticanceroso.
|
US20070212707A1
(en)
|
2004-07-23 |
2007-09-13 |
Ge Healthcare Uk Limited |
Cell cycle markers
|
MY148491A
(en)
|
2005-11-17 |
2013-04-30 |
Osi Pharm Inc |
FUSED BICYCLIC mTOR INHIBITORS
|
EP1981890A2
(en)
|
2006-01-25 |
2008-10-22 |
OSI Pharmaceuticals, Inc. |
UNSATURATED mTOR INHIBITORS
|
EP1996193A2
(en)
|
2006-03-13 |
2008-12-03 |
OSI Pharmaceuticals, Inc. |
Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
|
EP2178563A2
(en)
|
2007-07-06 |
2010-04-28 |
OSI Pharmaceuticals, Inc. |
Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
|
US20090149511A1
(en)
|
2007-10-30 |
2009-06-11 |
Syndax Pharmaceuticals, Inc. |
Administration of an Inhibitor of HDAC and an mTOR Inhibitor
|
WO2010006438A1
(en)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
KR20110090911A
(ko)
|
2008-10-31 |
2011-08-10 |
노파르티스 아게 |
포스파티딜이노시톨-3-키나아제 (pi3k) 억제제 및 mtor 억제제의 조합물
|
US8476282B2
(en)
*
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
JP2013509444A
(ja)
*
|
2009-10-30 |
2013-03-14 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
がんの治療方法及び治療用組成物
|
EP2776441A4
(en)
*
|
2011-11-08 |
2015-04-08 |
Intellikine Llc |
TREATMENT METHOD WITH MULTIPLE PHARMACEUTICAL AGENTS
|
AU2012335541B2
(en)
*
|
2011-11-11 |
2017-07-06 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
WO2013078440A2
(en)
*
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|